Skip to main content

Table 3 Summary of Grade 3 or 4 toxicities

From: Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years

CategoryConcomitant (N = 30)Adjuvant (N = 24)
Hematologic
 Neutropenia4 (13.3%)1 (4.2%)
 Lymphocytopenia15 (50%)11 (45.8%)
 Thrombocytopenia1 (3.3%)0
 Anemia1 (3.3%)1 (4.2%)
Hepatic
 Aspartate transaminase2 (6.7%)0
 Alanine transaminase2 (6.7%)1 (4.2%)
 Pulmonary (pneumonitis)2 (6.7%)1 (4.2%)
 Anorexia4 (13.3%)1 (4.2%)
 Hyponatremia3 (10.0%)0
 Hypokalemia1 (3.3%)0
 Skin rash4 (13.3%)1 (4.2%)